
Topic
Coverage Access
Formulary tiers, utilization management, patient support, and the access layer GoodRx and drug labels do not explain.

Pricing & Access· May 27, 2026 · 10 min read

Pricing & Access· May 27, 2026 · 15 min read
Vyvgart vs Vyvgart Hytrulo access guide

Biosimilars· May 27, 2026 · 11 min read
Xolair and Omlyclo omalizumab access guide

Pricing & Access· May 27, 2026 · 12 min read
Yescarta vs Tecartus CAR-T access guide
By Ran Chen#Oncology#CAR-T#Prior Authorization

Pipeline· May 26, 2026 · 8 min read
CagriSema pre-approval evidence review for obesity access teams
By Ran Chen#GLP-1#Amylin Analog#Obesity

Approvals· May 26, 2026 · 8 min read
Novel FDA drug approvals Q1-Q2 2026: the fifteen drugs and their formulary implications
By Ran Chen#FDA Approval#Novel Drug Approvals#GLP-1

Pricing & Access· May 26, 2026 · 7 min read
Veppanu coverage guide for ER+/HER2- breast cancer
By Ran Chen#PROTAC#Breast Cancer#Companion Diagnostic

Pricing & Access· May 25, 2026 · 9 min read
CGRP inhibitor access landscape: eight drugs, coverage, and payer criteria in 2026
By Ran Chen#CGRP#CNS and Migraine#Coverage Access

Pricing & Access· May 25, 2026 · 9 min read
PCSK9 inhibitor access landscape: Repatha, Praluent, Leqvio, and Lerochol in 2026
By Ran Chen#PCSK9#Cardiovascular#Coverage Access

Pricing & Access· May 24, 2026 · 12 min read
IL-23 inhibitor access landscape: Skyrizi, Stelara, Tremfya, Omvoh, and Ilumya in 2026
By Ran Chen#Immunology#IL-23 Inhibitor#Coverage Access